drugset / Trial / NCT00162812
Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin
Phase 2
Terminated
338 enrolled
Jules Bordet Institute
Centre Hospitalier du Luxembourg · collabCentre Paul Strauss · collabClinique Louis Cathy - Baudour - Belgium · collabClinique Saint Pierre Ottignies · collabClinique Ste Elisabeth - Namur - Belgium · collabFeculdade de Medicina da Universidade de Sao Paulo - Brasil · collabGustave Roussy, Cancer Campus, Grand Paris · collabHIS - Site Etterbeek - Ixelles - Belgium · collabUniversity Hospital of Crete · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
prospective evaluation of topoisomerase II alpha gene amplification and protein overexpression as markers predicting the efficacy of epirubicin in the primary treatment of breast cancer patients.
Timeline
- Start
- 2003-01
- Primary completion
- 2008-12
- Completion
- 2009-04
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual rate”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epirubicin | Small molecule | 100 mg/m2 | — |